Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

BioXcel Therapeutics Inc. (BTAI)

44.2   0.84 (1.94%) 10-01 09:45
Open: 44.01 Pre. Close: 43.36
High: 44.45 Low: 43.58
Volume: 52,664 Market Cap: 1,075M
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The company is headquartered in New Haven, Connecticut and currently employs 18 full-time employees. The firm uses novel artificial intelligence (AI) for drug re-innovation processes of approved product candidates to identify new therapeutic indices. Its principal clinical development programs are BXCL501 and BXCL701. BXCL501 is a sublingual thin film formulation of dexmedetomidine (Dex) designed for the acute treatment of agitation resulting from neurological and psychiatric disorders. BXCL701 is an immuno-oncology agent designed for the treatment of prostate and pancreatic cancer.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 43.927 - 44.105 44.105 - 44.274
Low: 41.409 - 41.601 41.601 - 41.784
Close: 43.364 - 43.674 43.674 - 43.968

Technical analysis

as of: 2020-09-30 4:39:29 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 53.65     One year: 59.17
Support: Support1: 38.29    Support2: 31.86
Resistance: Resistance1: 45.93    Resistance2: 50.66
Pivot: 44.94
Moving Average: MA(5): 42.86     MA(20): 44.52
MA(100): 47.89     MA(250): 29.39
MACD: MACD(12,26): -0.32     Signal(9): -0.16
Stochastic oscillator: %K(14,3): 27.40     %D(3): 29.54
RSI: RSI(14): 48.76
52-week: High: 71.50  Low: 3.76  Change(%): 631.7
Average Vol(K): 3-Month: 69633  10-Days: 48648

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
BTAI has closed above bottom band by 37.4%. Bollinger Bands are 30.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Tue, 29 Sep 2020
BioXcel Therapeutics (NASDAQ:BTAI) Cut to "Buy" at BidaskClub - MarketBeat

Thu, 24 Sep 2020
BioXcel Therapeutics Target of Unusually Large Options Trading (NASDAQ:BTAI) - MarketBeat

Wed, 23 Sep 2020
BioXcel Therapeutics: Opportunity Emerges During Pandemic While Mental Health Is Being Ignored - Seeking Alpha

Wed, 23 Sep 2020
BioXCel Therapeutics (NASDAQ:BTAI) A Hot Buy That Confuses Analysts - MarketBeat

Fri, 18 Sep 2020
Brokerages Anticipate BioXcel Therapeutics Inc (NASDAQ:BTAI) to Post -$0.80 EPS - MarketBeat

Wed, 09 Sep 2020
BioXcel Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference - Yahoo Finance

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 22
Shares Float (M) 13
% Held by Insiders 48.51
% Held by Institutions 28.52
Shares Short (K) 2,160
Shares Short P. Month (K) 2,810

Stock Financials

EPS -2.940
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 2.620
Profit Margin
Operating Margin
Return on Assets (ttm) -64.4
Return on Equity (ttm) -136.5
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -2.409
Qtrly Earnings Growth
Operating Cash Flow (M) -43
Levered Free Cash Flow (M) -23

Stock Valuations

PE Ratio -14.86
PEG Ratio
Price to Book value 16.67
Price to Sales
Price to Cash Flow -22.94

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.